Breast cancer (invasive) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-LI-FRAUMENI-SUSPICION-PREVENTION-GENETIC-COUNSELING`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-BREAST`
Sources	`SRC-NCCN-AML-2025` `SRC-NCCN-BREAST-2025` `SRC-NCCN-CNS-2025` `SRC-NCCN-SARCOMA`

Notes

STUB — v0.2-B hereditary pilot for Li-Fraumeni Syndrome. NCCN Genetic/Familial High-Risk Breast/Ovarian/Pancreatic and dedicated LFS testing guidance (Mai et al. NCI consortium, Bougeard et al. revised Chompret) as new SRC entities are v0.2-B authoring backlog. Cascade testing of confirmed-carrier first-degree relatives + interventions for confirmed carriers (RF-LI-FRAUMENI-CONFIRMED-CARRIER + IND-LI-FRAUMENI-CARRIER-*) are v0.2-B follow-up authoring.

Used By

Indication

IND-LI-FRAUMENI-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE - IND-LI-FRAUMENI-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE

Red flag

RF-LI-FRAUMENI-FAMILY-HISTORY-SUSPICION - Family pedigree or personal history meeting criteria suggestive of Li-Fraumeni Syndrome (...